Skip to main content
Fig. 3 | Cell Regeneration

Fig. 3

From: Modeling drug-induced liver injury and screening for anti-hepatofibrotic compounds using human PSC-derived organoids

Fig. 3

Predicting anti-hepatofibrotic drug efficacy based on high-content analysis using HLOs. A Representative images of fibrosis (Collagen I, green) in HLOs after administration of TGFβ1 at 10, 25, or 50 ng/mL for 3 days. Right: Quantification mean of Collagen fluorescent intensity. n = 15, *P < 0.05. B Gene expression analysis in HLOs after treatment with TGFβ1 at 10, 25, or 50 ng/mL for 3 days. n = 3, *P < 0.05. C tSNE analysis of potential anti-fibrotic effects of tested compounds in HLOs with HCA-based quantitative assessment screen. D Gene expression analysis in HLOs incubated with 25 ng/mL TGFβ and 1 μM anti-fibrotic compound (SD208, Imatinib, Cilofexor, or Silymarine) for 3 days. n = 3, *P < 0.05, versus TGFβ group. E HLOs were incubated with 25 ng/mL TGFβ and 1 μM anti-fibrotic compound (SD208, Imatinib) for 3 days. Scale bars, 50 μm. Representative images of fibrosis (Collagen I in green and DAPI in blue). Right: Quantification mean of fluorescent intensity. n = 15, *P < 0.05. F Gene expression analysis in HLOs incubated with 30 μM MTX and 1 μM SD208/ 4 μM Imatinib for 9 days. n = 3, *P < 0.05, versus MTX group. G HLOs were incubated with 30 μM MTX and 1 μM SD208/ 4 μM Imatinib for 9 days. Scale bars, 50 μm. Representative images of fibrosis (Collagen I in green and DAPI in blue). Right: Quantification mean of fluorescent intensity. n = 15, *P < 0.05. Values represent means with SEM. P values were assessed by one-way ANOVA with Dunnett’s multiple comparisons test (B, D, F), and Kruskal–Wallis tests (A, E, G)

Back to article page